Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Robert H. Vonderheide, MD, DPhil
Advertisement
Articles by Robert H. Vonderheide, MD, DPhil
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
3
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
